Released on: December 6, 2007, 3:23 am

Press Release Author: Rene Hermes

Industry: Healthcare

Press Release Summary: Munich, Germany - December 6th, 2007 - Definiens, the number
one Enterprise Image IntelligenceT company, today unveiled the release of Definiens
TissueMap 2.0, highlighting the company's focus on oncology research. The image
analysis software application is especially designed for the detailed, automated
morphometric quantification of biomarkers of nuclei or cell bodies in epithelial
tumors or xenografts. The application features the detection of viable and necrotic
tissue in xenografts, as well as regions of IHC (DAB) positively stained nuclei or
cells in the viable tissue. This enables pathologists to automate the process of
complex or highly apoptotic xenograft analysis in oncology research.

Press Release Body: Effective imaging technologies support pharmaceutical
development in oncology
The discovery and application of oncology biomarkers have enhanced opportunities for
individual disease treatment by identifying new drug targets. They therefore have a
significant impact on the entire process of drug development including the emergence
and growth of imaging technologies utilized to acquire accurate measurements of
disease parameters.

The effective use of imaging technologies, such as Definiens TissueMap 2.0,
significantly improves the selection and prioritization of quality candidates early
in the drug development pipeline. This results in substantial cost savings and
faster time-to-market as poorer drug candidates are removed early in the discovery
process.


Assessment of any biomarkers targeting an antigen located in the nucleus or cell body
Definiens TissueMap 2.0 reliably identifies areas and structures of interest in
image data allowing researchers to distinguish between viable and necrotic tumor
areas and to quantify markers. It offers:
o Full tissue slide analysis

o Fast and reproducible results

o Platform independence and connectivity

o Easy customization

o Precise measurement of morphological parameters

Definiens TissueMap 2.0 encompasses the assessment of any biomarkers targeting an
antigen located in the nucleus such as proliferation markers (Ki67, PCNA, BrdU,
etc.), apoptosis markers such as Cap3 as well as estrogen or progesterone receptors.
Antibodies or markers co-/located in the cell body, such as cytokeratines (CD31,
AE1/3, etc.) and other proteins (CD45, CD23 or similar) can also be evaluated.

Comprehensive software for quantification regardless of staining methodology
Definiens TissueMap 2.0 enables the quantification of biomarker expression patterns
in image data regardless of staining methodology. The software application
effectively analyzes image data in oncology research, including cases involving poor
staining technique and data obtained from heterogeneous equipment.

Definiens TissueMap 2.0 enables the automated detection of relevant morphological
structure in tissue and tumor sections. It improves research results through
increased data accuracy, consistency and reproducibility.

New information concerning Definiens TissueMap 2.0 was presented at the 7th World
Drug Discovery & Development Summit 2007 in Cologne, Germany, December 4-5, 2007,
which brought together leading pharmaceutical and biotech professionals to discuss
key scientific and strategic challenges.



Definiens in Life Sciences
By automating image analysis on an enterprise level, Definiens supports Life Science
organizations to analyze and interpret vast numbers of images accurately and
consistently. Definiens improves the measurement of cell assays, the examination of
tissue samples and the interpretation of non-invasive imaging, enabling high-content
screening, digital pathology and translational medicine.

About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing and
interpreting images on every scale, from microscopic cell structures to satellite
images. The Definiens Cognition Network Technology®, developed by Nobel laureate
Prof. Gerd Binnig and his team, is an advanced and robust context-based technology
designed to fulfill the image analysis requirements of the Life and Earth sciences
markets. The technology is modeled on the powerful human cognitive perception
processes to extract intelligence from images. Definiens provides organizations with
faster image analysis results, allowing deeper insights enabling better business
decisions. The company is headquartered in Munich, Germany and has offices
throughout the United States. Further information is available at www.definiens.com.

Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens
eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or
registered trademarks of Definiens.




Web Site: http://www.definiens.com

Contact Details: Press contacts:
Definiens
Rene Hermes, Vice President Marketing
rhermes@definiens.com


Lucy Turpin Communications GmbH
Eva Hildebrandt
definiens@lucyturpin.com
+49 (0)89 417761-14